ArticleCirculation research2013
Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism.
Article in Circulation research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Choice of Antiplatelet vs. Anticoagulant for Blunt Cerebrovascular Injury.Life (Basel, Switzerland) · 2025Review
- Full dose of cangrelor in the acute treatment of small ruptured cerebral aneurysms with flow diverters: a single center experience.Acta neurochirurgica · 2025Article
- Quantitative MALDI imaging of aspirin metabolites in mouse models of triple-negative breast cancer.Theranostics · 2025Article
- Review
- Longitudinal exposure to consumer product chemicals and changes in plasma oxylipins in pregnant women.Environment international · 2021Article
- Platelet and myeloid cell phenotypes in a rat model of Fabry disease.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021Article
- Multifaceted Functions of Platelets in Cancer: From Tumorigenesis to Liquid Biopsy Tool and Drug Delivery System.International journal of molecular sciences · 2020Review
- Time-Dependent Hypotensive Effect of Aspirin in Mice.Arteriosclerosis, thrombosis, and vascular biology · 2018Article
- P2YFrontiers in pharmacology · 2018Review
- Platelets as crucial partners for tumor metastasis: from mechanistic aspects to pharmacological targeting.Cellular and molecular life sciences : CMLS · 2017Review
- Oleocanthal-rich extra virgin olive oil demonstrates acute anti-platelet effects in healthy men in a randomized trial.Journal of functional foods · 2017Article
- Modulation of miR-26a-5p and miR-15b-5p Exosomal Expression Associated with Clopidogrel-Induced Hepatotoxicity in HepG2 Cells.Frontiers in pharmacology · 2017Article
- A broad-spectrum lipidomics screen of antiinflammatory drug combinations in human blood.JCI insight · 2016Article
- Eicosanoid storm in infection and inflammation.Nature reviews. Immunology · 2015Review
- Novel insights into the regulation of cyclooxygenase-2 expression by platelet-cancer cell cross-talk.Biochemical Society transactions · 2015Review
- Platelet Gi protein Gαi2 is an essential mediator of thrombo-inflammatory organ damage in mice.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Platelet lipidomics: modern day perspective on lipid discovery and characterization in platelets.Circulation research · 2014Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The development of drugs that inhibit platelets has been driven by a combination of clinical insights, fundamental science, and sheer luck. The process has evolved as the days of stumbling on therapeutic gems, such as aspirin, have long passed and have been replaced by an arduous process in which a drug is designed to target a specific protein implicated in a well-characterized pathophysiological process, or so we would like to believe. The development of antiplatelet therapy illustrates the importance of understanding the mechanisms of disease and the pharmacology of the compounds we develop, coupled with careful clinical experimentation and observation and, yes, still, a fair bit of luck.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.